These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15899833)

  • 1. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
    Huang X; Bennett M; Thorpe PE
    Cancer Res; 2005 May; 65(10):4408-16. PubMed ID: 15899833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
    Ran S; He J; Huang X; Soares M; Scothorn D; Thorpe PE
    Clin Cancer Res; 2005 Feb; 11(4):1551-62. PubMed ID: 15746060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids.
    He J; Luster TA; Thorpe PE
    Clin Cancer Res; 2007 Sep; 13(17):5211-8. PubMed ID: 17785577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
    Ran S; Downes A; Thorpe PE
    Cancer Res; 2002 Nov; 62(21):6132-40. PubMed ID: 12414638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
    Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
    Menendez JA; Ropero S; Lupu R; Colomer R
    Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.
    Wu H; Xin Y; Zhao J; Sun D; Li W; Hu Y; Wang S
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):879-87. PubMed ID: 21290245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells.
    Luster TA; He J; Huang X; Maiti SN; Schroit AJ; de Groot PG; Thorpe PE
    J Biol Chem; 2006 Oct; 281(40):29863-71. PubMed ID: 16905548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
    Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
    Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
    Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice.
    Suto A; Kubota T; Fukushima M; Ikeda T; Takeshita T; Ohmiya H; Kitajima M
    Oncol Rep; 2006 Jun; 15(6):1517-22. PubMed ID: 16685389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.